Canaccord Genuity Maintains Buy on Immunogen, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on Immunogen (NASDAQ: IMGN) and raises the price target from $15 to $19.
June 05, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains Buy rating on Immunogen and raises the price target from $15 to $19.
The raised price target by Canaccord Genuity analyst John Newman indicates a positive outlook for Immunogen's stock. This news is likely to have a positive short-term impact on the stock price as it shows increased confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100